Amylyx Pharmaceuticals (AMLX) to Release Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) will post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Amylyx Pharmaceuticals to post earnings of $0.24 per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. The company had revenue of $108.45 million for the quarter, compared to analyst estimates of $106.40 million. Amylyx Pharmaceuticals had a net margin of 12.94% and a return on equity of 12.39%. During the same period in the prior year, the firm earned ($0.65) EPS. On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Up 1.5 %

Shares of AMLX stock traded up $0.03 during trading hours on Friday, hitting $2.03. 1,473,737 shares of the company were exchanged, compared to its average volume of 2,782,921. The firm has a market cap of $138.06 million, a PE ratio of 2.90 and a beta of -0.68. Amylyx Pharmaceuticals has a 1 year low of $1.70 and a 1 year high of $30.50. The firm has a fifty day moving average of $5.77 and a 200 day moving average of $11.90.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 1,540 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total value of $28,844.20. Following the completion of the sale, the insider now owns 81,372 shares of the company's stock, valued at $1,524,097.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO James M. Frates sold 1,792 shares of the firm's stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $33,564.16. Following the completion of the sale, the chief financial officer now owns 134,784 shares of the company's stock, valued at $2,524,504.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gina Mazzariello sold 1,540 shares of the firm's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total transaction of $28,844.20. Following the sale, the insider now directly owns 81,372 shares of the company's stock, valued at approximately $1,524,097.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,305 shares of company stock valued at $193,098. 11.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently weighed in on AMLX shares. Evercore ISI reiterated an "in-line" rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. Robert W. Baird lowered shares of Amylyx Pharmaceuticals from an "outperform" rating to a "neutral" rating in a report on Monday, March 11th. Mizuho lowered shares of Amylyx Pharmaceuticals from a "buy" rating to a "neutral" rating in a report on Monday, March 18th. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of Amylyx Pharmaceuticals in a report on Monday, April 8th. Finally, The Goldman Sachs Group reissued a "neutral" rating on shares of Amylyx Pharmaceuticals in a research report on Friday, March 8th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $32.67.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.